Cross Timbers Royalty Trust CRT
Set alert
12.86 USD -0.23 -1.76%
At close · Nov 2
12.86 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
12.71 Day range 13.21
7.34 52-week range 14.63
- YTD
- +61.76%
- 1 year
- +71.93%
- Open
- 12.85
- Prev close
- 13.09
- Mkt cap
- 77.16M
- Vol
- 8.70K
- Avg vol
- 25.48K
- EPS
- 0.53
- P/E
- 24.26
- Div yield
- 10.81%
More statistics
- Low
- 12.71
- High
- 13.21
- Forward P/E
- 0.00
- Beta
- 0.54
- Short ratio
- 0.45
- Inst. own
- 2.63%
- Dividend
- 1.08
- Ex-div date
- Oct 30, 2024
- 50-d avg
- 10.39
- 200-d avg
- 11.50
- 1y target
- 0.00
3M chart
Events in this range
- Aug 31, 2026Dividend: 0.067892
- Sep 30, 2026Dividend: 0.064277
- Oct 30, 2026Dividend: 0.27791
Signals (15)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 2026 | 14 hours ago |
| RSI: Overbought | Oct 26, 2026 | 1 week ago |
| RSI: Overbought | Oct 21, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 8, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 5, 2026 | 4 weeks ago |
| SMA: Bullish | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 24, 2026 | 1 month ago |
| RSI: Overbought | Sep 8, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 4, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| RSI: Overbought | Aug 21, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 14, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 11, 2026 | 2 months ago |
Key statistics
- Market cap
- 57.42M
- Enterprise value
- 59.00M
- Trailing P/E
- 8.47
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 6.61
- Price / book
- 21.51
- EPS (TTM)
- 1.13
- Beta
- 0.54
- Dividend yield
- 10.81%
- Payout ratio
- 100.00%
- Profit margin
- 88.67%
- Revenue (TTM)
- 8.69M
- Revenue growth
- -50.30%
- Free cash flow
- 0
- Total cash
- 1.18M
- Total debt
- 0
- Return on equity
- 288.74%
- Shares outstanding
- 6.00M
- Short % of float
- 0.19%
- 50-day average
- 10.39
- 200-day average
- 11.50
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | 0.25 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | 0.22 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | 0.25 | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | 0.40 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | 0.41 | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | 0.51 | — | — |
About Cross Timbers Royalty Trust
Cross Timbers Royalty Trust operates as an express trust in the United States. It holds 90% net profits interests in certain producing and nonproducing royalty and overriding royalty interest properties in Texas, Oklahoma, and New Mexico; and 75% net profits working interest in four properties in Texas and three properties in Oklahoma. The company was founded in 1991 and is based in Dallas, Texas.
- Sector
- Energy
- Industry
- Oil & Gas E&P
- Country
- United States
- Website
- crt-crosstimbers.com
News
- IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
- Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
- Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
- CROSS TIMBERS ROYALTY TRUST DECLARES OCTOBER CASH DISTRIBUTION
- New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
- Analyzing Cross Timbers Royalty Trust (NYSE:CRT) and Navigator (NYSE:NVGS)
- Cross Timbers Royalty Trust (CRT) To Go Ex-Dividend on September 30th
- CROSS TIMBERS ROYALTY TRUST DECLARES SEPTEMBER CASH DISTRIBUTION
- Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
- Innate Pharma Reports First Half 2026 Business Update and Financial Results
Your note
Sign in to keep a note on CRT — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Mraz, Amerine & Associates, Inc. | 0.76% | 45,876 | 439.03K | Sep 29, 2024 |
| UBS Group AG | 0.41% | 24,876 | 238.06K | Sep 29, 2024 |
| NewEdge Advisors, LLC | 0.35% | 20,777 | 198.84K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.29% | 17,119 | 163.83K | Sep 29, 2024 |
| Morgan Stanley | 0.25% | 15,052 | 144.05K | Sep 29, 2024 |
| LPL Financial LLC | 0.24% | 14,366 | 137.48K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Series Portfolios Tr-Unusual Whales Subversive Republican Trading ETF | 0.00% | 69 | 660 | Dec 30, 2023 |